TARDBP and amyotrophic lateral sclerosis: Although no direct evidence currently links astrocytic m6A modifications to ALS pathology, mutations in RNA-binding proteins such as Fused in sarcoma (FUS) and TAR DNA-binding protein-43 (TDP-43), which are associated with altered m6A modifications, imply a potential epitranscriptomic mechanism that warrants further investigation [76,77,133,134].